Twist Bioscience Corporation (NASDAQ:TWST) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Twist Bioscience Corporation (NASDAQ:TWST) have been assigned a consensus recommendation of “Moderate Buy” from the eleven ratings firms that are covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating and nine have issued a buy rating on the company. The average 12-month target price among brokers that have covered the stock in the last year is $44.6667.

A number of research analysts have issued reports on the company. TD Cowen boosted their target price on Twist Bioscience from $32.00 to $43.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. Stephens started coverage on Twist Bioscience in a research report on Monday, November 3rd. They issued an “overweight” rating and a $41.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a research note on Monday, December 29th. Evercore ISI reaffirmed an “outperform” rating and issued a $42.00 price target on shares of Twist Bioscience in a research note on Monday, January 5th. Finally, Barclays upped their price target on shares of Twist Bioscience from $37.00 to $39.00 and gave the company an “overweight” rating in a report on Monday, December 15th.

Twist Bioscience Stock Performance

Shares of NASDAQ:TWST opened at $41.41 on Friday. The company has a current ratio of 3.64, a quick ratio of 3.33 and a debt-to-equity ratio of 0.03. Twist Bioscience has a 1-year low of $23.30 and a 1-year high of $55.33. The stock has a market capitalization of $2.54 billion, a P/E ratio of -31.61 and a beta of 2.19. The business has a 50-day moving average price of $32.42 and a two-hundred day moving average price of $31.26.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings data on Friday, November 14th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.05). The company had revenue of $99.01 million during the quarter, compared to the consensus estimate of $97.40 million. Twist Bioscience had a negative net margin of 20.63% and a negative return on equity of 27.40%. Equities analysts predict that Twist Bioscience will post -2.12 earnings per share for the current year.

Insider Transactions at Twist Bioscience

In related news, CEO Emily M. Leproust sold 31,379 shares of the stock in a transaction on Thursday, October 30th. The shares were sold at an average price of $31.44, for a total transaction of $986,555.76. Following the completion of the transaction, the chief executive officer owned 738,809 shares in the company, valued at approximately $23,228,154.96. This represents a 4.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Paula Green sold 6,920 shares of the firm’s stock in a transaction on Thursday, October 30th. The shares were sold at an average price of $31.44, for a total transaction of $217,564.80. Following the completion of the transaction, the senior vice president directly owned 143,271 shares of the company’s stock, valued at approximately $4,504,440.24. This trade represents a 4.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 66,437 shares of company stock valued at $2,136,365 in the last ninety days. Corporate insiders own 3.08% of the company’s stock.

Institutional Investors Weigh In On Twist Bioscience

Several large investors have recently made changes to their positions in the stock. Quarry LP acquired a new position in Twist Bioscience during the third quarter worth approximately $28,000. Smartleaf Asset Management LLC increased its holdings in shares of Twist Bioscience by 70.6% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock worth $29,000 after acquiring an additional 442 shares during the last quarter. National Bank of Canada FI bought a new stake in Twist Bioscience in the 3rd quarter valued at $46,000. Mirae Asset Global Investments Co. Ltd. raised its stake in Twist Bioscience by 15.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company’s stock valued at $85,000 after acquiring an additional 302 shares during the period. Finally, Geneos Wealth Management Inc. acquired a new stake in Twist Bioscience during the 2nd quarter valued at $97,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.